The use of levofloxacin in a patient with leptospirosis

Davut Ozdemir; İrfan Sencan; Tevfik Yavuz; Oguz Karabay; Ertugrul Guclu

The use of levofloxacin in a patient with leptospirosis

Year 2006, Volume: 8 Issue: 1, 14 - 15, 01.03.2006

Davut Ozdemir İrfan Sencan Tevfik Yavuz Oguz Karabay Ertugrul Guclu

References

Shalit I, Barnea A, Shahar A: Efficacy of ciprofloxacin againts interrogans serogroup icterohaemorrhagiae. Antimicrob Agents Chemother. 33: 788-789, 1989. Leptospira
Sünbül M: Leptospiroz. ANKEM Derg. 20 (Ek2): 219-221, 2006.
Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM: Leptospirosis: a zoonotic disease of globalimportance. Lancet Infect Dis . 3: 757–771, 2003.
http://www.med.monash.edu.au/microbiol ogy/staff/adler/leptoguidelines2003pdf
Takashima I, Ngoma M, Hashimoto N: Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans. Antimicrob Agents Chemother. 37: 901- 902, 1993.
Truccola J, Charavay F, Merien F, Perolat P: Quantitative PCR assay to evaluate ampicillin, ofloxacin, and doxycycline for treatment of experimental leptospirosis. Antimicrob Agents Chemother. 46: 848- 852, 2002.
Schonberg A: Studies on the effect of antibiotic substances on leptospires and their cultivation from material with a high bacterial count. Zentralbl Bacteriol A. 249: 400-406, 1981.
Sugunan AP, Natarajaseenivasan K, Vijayachari P, Seghal SC: Percutaneous exposure resulting in laboratory-acquired leptospirosis -a case report. J Med Microbiol. 53: 1258-1262, 2004.
Mancel E, Merrien F, Pesenti L, Salino D, Angibaud G, Perolat P: Clinical aspects of ocular leptospirosis in New Caledonia (South Pacific). Aust N Z J Ophthalmol. 27: 380– 386, 1999.
National Committee for Clinical Laboratory Standards: dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa,1997.

The use of levofloxacin in a patient with leptospirosis

Year 2006, Volume: 8 Issue: 1, 14 - 15, 01.03.2006

Davut Ozdemir İrfan Sencan Tevfik Yavuz Oguz Karabay Ertugrul Guclu

References

Shalit I, Barnea A, Shahar A: Efficacy of ciprofloxacin againts interrogans serogroup icterohaemorrhagiae. Antimicrob Agents Chemother. 33: 788-789, 1989. Leptospira
Sünbül M: Leptospiroz. ANKEM Derg. 20 (Ek2): 219-221, 2006.
Bharti AR, Nally JE, Ricaldi JN, Matthias MA, Diaz MM, Lovett MA, Levett PN, Gilman RH, Willig MR, Gotuzzo E, Vinetz JM: Leptospirosis: a zoonotic disease of globalimportance. Lancet Infect Dis . 3: 757–771, 2003.
http://www.med.monash.edu.au/microbiol ogy/staff/adler/leptoguidelines2003pdf
Takashima I, Ngoma M, Hashimoto N: Antimicrobial effects of a new carboxyquinolone drug, Q-35, on five serogroups of Leptospira interrogans. Antimicrob Agents Chemother. 37: 901- 902, 1993.
Truccola J, Charavay F, Merien F, Perolat P: Quantitative PCR assay to evaluate ampicillin, ofloxacin, and doxycycline for treatment of experimental leptospirosis. Antimicrob Agents Chemother. 46: 848- 852, 2002.
Schonberg A: Studies on the effect of antibiotic substances on leptospires and their cultivation from material with a high bacterial count. Zentralbl Bacteriol A. 249: 400-406, 1981.
Sugunan AP, Natarajaseenivasan K, Vijayachari P, Seghal SC: Percutaneous exposure resulting in laboratory-acquired leptospirosis -a case report. J Med Microbiol. 53: 1258-1262, 2004.
Mancel E, Merrien F, Pesenti L, Salino D, Angibaud G, Perolat P: Clinical aspects of ocular leptospirosis in New Caledonia (South Pacific). Aust N Z J Ophthalmol. 27: 380– 386, 1999.
National Committee for Clinical Laboratory Standards: dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa,1997.

There are 10 citations in total.

Details

Primary Language	English
Journal Section	Editorial
Authors	Davut Ozdemir This is me İrfan Sencan This is me Tevfik Yavuz This is me Oguz Karabay This is me Ertugrul Guclu This is me
Publication Date	March 1, 2006
Published in Issue	Year 2006 Volume: 8 Issue: 1

Cite

APA	Ozdemir, D., Sencan, İ., Yavuz, T., Karabay, O., et al. (2006). The use of levofloxacin in a patient with leptospirosis. Duzce Medical Journal, 8(1), 14-15.
AMA	Ozdemir D, Sencan İ, Yavuz T, Karabay O, Guclu E. The use of levofloxacin in a patient with leptospirosis. Duzce Med J. March 2006;8(1):14-15.
Chicago	Ozdemir, Davut, İrfan Sencan, Tevfik Yavuz, Oguz Karabay, and Ertugrul Guclu. “The Use of Levofloxacin in a Patient With Leptospirosis”. Duzce Medical Journal 8, no. 1 (March 2006): 14-15.
EndNote	Ozdemir D, Sencan İ, Yavuz T, Karabay O, Guclu E (March 1, 2006) The use of levofloxacin in a patient with leptospirosis. Duzce Medical Journal 8 1 14–15.
IEEE	D. Ozdemir, İ. Sencan, T. Yavuz, O. Karabay, and E. Guclu, “The use of levofloxacin in a patient with leptospirosis”, Duzce Med J, vol. 8, no. 1, pp. 14–15, 2006.
ISNAD	Ozdemir, Davut et al. “The Use of Levofloxacin in a Patient With Leptospirosis”. Duzce Medical Journal 8/1 (March 2006), 14-15.
JAMA	Ozdemir D, Sencan İ, Yavuz T, Karabay O, Guclu E. The use of levofloxacin in a patient with leptospirosis. Duzce Med J. 2006;8:14–15.
MLA	Ozdemir, Davut et al. “The Use of Levofloxacin in a Patient With Leptospirosis”. Duzce Medical Journal, vol. 8, no. 1, 2006, pp. 14-15.
Vancouver	Ozdemir D, Sencan İ, Yavuz T, Karabay O, Guclu E. The use of levofloxacin in a patient with leptospirosis. Duzce Med J. 2006;8(1):14-5.